Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Healthcare & Pipeline Overview

Corbus Pharmaceuticals Holdings, Inc. is a biotechnology firm specializing in immune-modulating therapies for immuno-oncology and fibrotic diseases. Their lead drug, lenabasum, targets cannabinoid receptor type 2 (CB2) and is currently in Phase II trials, positioning them in the competitive landscape of autoimmune and fibrotic disease treatments.

What Is the Investment Thesis for CRBP?

Corbus Pharmaceuticals presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful development and commercialization of lenabasum, currently in Phase II trials for systemic lupus erythematosus. Positive clinical trial results could significantly increase the company's valuation. The anti-integrin monoclonal antibody programs, CRB-601 and CRB-602, represent additional potential value drivers in the oncology and fibrosis spaces. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for additional funding. With a market capitalization of $149M and a beta of 2.79, CRBP exhibits substantial volatility. The absence of a dividend reflects the company's focus on reinvesting capital into research and development. Successful advancement of its pipeline could yield substantial returns, but investors should be aware of the inherent risks associated with biotechnology investments.

Based on FMP financials and quantitative analysis

CRBP Key Highlights

Lenabasum is in Phase II clinical trials for the treatment of systemic lupus erythematosus, representing a potential near-term value driver.

• CRB-601, an anti-integrin monoclonal antibody (mAb), targets cancer and fibrosis by inhibiting TGFß activation.
• CRB-602, another anti-avß6/avß8 mAb, is being developed to block TGFß activation for the treatment of fibrotic diseases.
• The company has a licensing agreement with Jenrin Discovery, LLC, providing access to a library of approximately 600 compounds.
• Corbus is also developing a cannabinoid receptor type 1 inverse agonist program for metabolic disorders and fibrotic diseases.

Who Are CRBP's Competitors?

CRBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CRBP's Key Strengths?

Novel drug candidates targeting unmet medical needs.

• Proprietary technology and intellectual property.
• Experienced management team.
• Licensing agreements providing access to a library of compounds.

What Are CRBP's Weaknesses?

Limited financial resources.

• Dependence on successful clinical trial outcomes.
• High risk of drug development failure.
• Small number of employees.

What Could Drive CRBP Stock Higher?

Phase II clinical trial results for lenabasum in systemic lupus erythematosus.

• Development of CRB-601 and CRB-602, anti-integrin monoclonal antibodies, for cancer and fibrosis.
• Advancement of cannabinoid receptor type 1 inverse agonist program for metabolic disorders.
• Potential licensing and partnership agreements with other pharmaceutical companies.

What Are the Key Risks for CRBP?

Financial-distress signal — its Altman Z-Score of -4.63 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-70.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for lenabasum or other drug candidates.
• Regulatory hurdles and delays in obtaining marketing approvals.
• Competition from other pharmaceutical companies developing similar therapies.
• Dependence on securing additional funding to support research and development activities.
• Patent expirations and loss of exclusivity for key drug candidates.

What Are the Growth Opportunities for CRBP?

• Lenabasum's Clinical Advancement: Successful completion of Phase II clinical trials for systemic lupus erythematosus and subsequent progression to Phase III trials represent a significant growth opportunity. Positive clinical data would validate the drug's efficacy and safety, potentially leading to regulatory approval and commercialization. The market for lupus treatments is substantial, with a global market size estimated at several billion dollars. Timeline: Ongoing, with Phase II results expected in the near term.
• Expansion of Anti-integrin mAb Programs: The development of CRB-601 and CRB-602, anti-integrin monoclonal antibodies, offers growth potential in the oncology and fibrosis markets. These mAbs target TGFß activation, a key pathway in cancer and fibrotic disease progression. Successful preclinical and clinical development could lead to novel therapies for these diseases. Timeline: Ongoing, with preclinical and early clinical development underway.
• Cannabinoid Receptor Type 1 Inverse Agonist Program: Corbus's cannabinoid receptor type 1 inverse agonist program targets metabolic disorders such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis. These indications represent large and growing markets, driven by increasing prevalence of these conditions. Successful development of these agonists could provide novel treatment options. The market for obesity and diabetes treatments is estimated at tens of billions of dollars. Timeline: Ongoing, with early-stage development.
• Licensing and Partnerships: Corbus's licensing agreement with Jenrin Discovery, LLC, provides access to a library of approximately 600 compounds, expanding their drug discovery capabilities. Strategic partnerships with other pharmaceutical companies could also accelerate the development and commercialization of their pipeline. Licensing deals can provide upfront payments, milestone payments, and royalties, boosting revenue. Timeline: Ongoing, with potential for new deals in the near future.
• Expansion into New Indications: Corbus could explore expanding the indications for its existing pipeline candidates. For example, lenabasum could be investigated for other autoimmune diseases beyond systemic lupus erythematosus. This strategy could leverage existing clinical data and development expertise to address additional unmet medical needs. The market for autoimmune disease therapies is substantial and growing. Timeline: Ongoing, with potential for new clinical trials in the future.

What Are CRBP's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in immune modulation and fibrosis.
• Licensing agreements providing access to novel compounds.
• Clinical trial data demonstrating safety and efficacy.

What Does CRBP Do?

Corbus Pharmaceuticals Holdings, Inc., founded in 2009 and based in Norwood, Massachusetts, is a biopharmaceutical company dedicated to the development and commercialization of innovative immune modulators. The company's primary focus is on addressing unmet medical needs in immuno-oncology and fibrotic diseases. Their lead product candidate, lenabasum, is an oral, selective cannabinoid receptor type 2 (CB2) agonist. Lenabasum is currently in Phase II clinical development for the treatment of systemic lupus erythematosus. In addition to lenabasum, Corbus is advancing a pipeline of novel anti-integrin monoclonal antibodies (mAbs), including CRB-601 and CRB-602. CRB-601 is designed to inhibit the activation of transforming growth factor ß (TGFß) for the treatment of cancer and fibrosis, while CRB-602 blocks the activation of TGFß for fibrotic diseases. Corbus is also developing a cannabinoid receptor type 1 inverse agonist program targeting metabolic disorders such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis, as well as fibrotic diseases affecting the lung, heart, kidney, and liver. The company has a licensing agreement with Jenrin Discovery, LLC, granting them access to the Jenrin library of approximately 600 compounds and associated patent filings, enhancing their drug discovery capabilities.

What Products and Services Does CRBP Offer?

• Develop immune modulators for immuno-oncology and fibrosis diseases.
• Develop lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2).
• Develop CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis.
• Develop CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.
• Develop cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders.
• Target diseases including obesity, diabetic nephropathy, and nonalcoholic steatohepatitis.

How Does CRBP Make Money?

• Develop and license novel drug candidates.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved drugs directly or through partnerships.

What Industry Does CRBP Operate In?

Corbus Pharmaceuticals operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for immune modulators and therapies for fibrotic diseases is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases. Corbus competes with larger pharmaceutical companies and specialized biotech firms developing similar therapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies. The biotechnology sector is also subject to significant market volatility, influenced by clinical trial results, regulatory decisions, and funding availability.

Who Are CRBP's Key Customers?

• Patients suffering from immuno-oncology diseases.
• Patients suffering from fibrosis diseases.
• Healthcare providers who prescribe and administer the company's drugs.
• Pharmaceutical companies that may partner with Corbus for drug development and commercialization.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Valuation Context

Valued at $149M, CRBP is classified as a micro-cap stock. Analyst price targets span from $33.00 to $35.00, with a consensus of $33.67. At the current price of $8.04, that implies approximately 319% upside potential. Relative to its peer group, CRBP's quantitative score of 26/100 is below the peer average of 77/100.

CRBP Revenue & Earnings Trend

In Jun 2026, CRBP generated $0 in top-line revenue. The company recorded a net loss of $35.0M, with diluted EPS of $-1.81. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CRBP averaged $-1.62 in diluted EPS.

Company Profile

Corbus Pharmaceuticals Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Norwood, US. The company is led by CEO Yuval Cohen. CRBP has traded publicly since 2014.

Return on equity for Corbus Pharmaceuticals Holdings, Inc. stands at -70.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -58.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -62.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -67.7%, the inverse of the P/E and a quick read on earnings relative to price.

Corbus Pharmaceuticals Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.63 places it in the distress zone, a signal of elevated financial risk.

Corbus Pharmaceuticals Holdings, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.6% below estimates on average.

Wall Street analysts project Corbus Pharmaceuticals Holdings, Inc. revenue of about $1.7M for fiscal 2026, with EPS near $-5.43. The estimate reflects 9 contributing analysts.

Over the past six months, Corbus Pharmaceuticals Holdings, Inc. insiders filed 24 SEC Form 4 transactions — 5 sales and 19 purchases. On net that is roughly 591K shares acquired (about $4.7M) — insiders putting money in tends to read as conviction.

CRBP Financials

CRBP Latest News

CRBP Analyst Consensus

CRBP MoonshotScore

What Investors Ask About Corbus Pharmaceuticals Holdings, Inc. (CRBP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources